CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06925542
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:48.230669+00:00
Published At: 2025-12-17T00:00:00+00:00
Record Updated At: 2025-12-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["SLE (Systemic Lupus)", "Lupus Erythematosus, Systemic", "Lupus Nephritis", "Systemic Sclerosis", "Inflammatory Myopathy, Idiopathic", "Myositis", "Diffuse Cutaneous Systemic Sclerosis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-17"
protocolSection.identificationModule.nctId: "NCT06925542"
protocolSection.identificationModule.officialTitle: "A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.